ASX:BOT

4 stories mentioning ASX:BOTUpdated 28d ago

Every FINWIRES story that references ASX:BOT, newest first.

Botanix Pharmaceuticals Receives Notice of Allowance for US Patent Covering Sofdra Drug Substance

Botanix Pharmaceuticals (ASX:BOT) said the US Patent and Trademark Office issued a notice of allowance for a patent covering the drug substance for Sofdra, the company's treatment for primary axillary hyperhidrosis in patients who are at least nine years old, according to a Monday filing with the Australian bourse.The patent relates to commercially relevant innovations associated with the sofpironium drug substance. Once issued, it will provide additional protections on top of other patents that cover Sofdra's commercial drug substance into May 2040, the company said.Primary axillary hyperhidrosis is a medical condition characterized by uncontrollable and excessive underarm sweating.

ASX:BOT

Asia98d ago

Botanix Pharmaceuticals Appoints Chief Operating Officer; Shares Fall 4%

Botanix Pharmaceuticals (ASX:BOT) has promoted Paul Seaback to chief operating officer, according to a Monday filing with the Australian bourse.Seaback joined the commercial dermatology company in November 2024 as chief technical officer.Shares of Botanix Pharmaceuticals fell 4% in recent Monday trade.

ASX:BOT

Asia101d ago

Botanix Pharmaceuticals' Q3 Results Beat Estimates, Says Euroz Hartleys

Botanix Pharmaceuticals (ASX:BOT) fiscal third quarter results beat Euroz Hartleys' estimates with the fifth consecutive quarter of prescription growth, according to a Thursday Euroz Hartleys note.Total prescriptions increased 5% quarter-on-quarter to 26,684, slightly above Euroz Hartleys' estimates of 26,500. and gross-to-net yield declined quarter-on-quarter from 24% to 18%, in line with the research firm's expectations.The company's current AU$60 million enterprise value does not fully reflect the AU$34.5 million of inventory held on the balance sheet, the research firm added.The research firm believes that Botanix's Sofdra has the makings of a category leader in hyperhidrosis, a dermatology condition, and added that consistent prescription growth alone, or the addition of a new product to its platform, can potentially re-rate the stock "materially higher."Euroz Hartkeys has a buy rating on Botanix Pharmaceuticals with a price target of AU$0.25.

ASX:BOT

Asia116d ago

Botanix Signs Term Sheet With Second Active Pharmaceutical Ingredient Supplier; Shares Jump 6%

Botanix Pharmaceuticals (ASX:BOT) agreed to terms with PPL Pharma Solutions Riverview for a proposed manufacturing and supply arrangement for Sofdra, the company's treatment for primary axillary hyperhidrosis, or excessive underarm sweating, according to a Thursday Australian bourse filing.Under the terms, PPL Pharma will start development services and serve as an alternate commercial supplier of sofpironium bromide, the active pharmaceutical ingredient in Sofdra.The technical transfer will start immediately, and the companies will negotiate a definitive commercial active pharmaceutical ingredient supply agreement, the filing said. The establishment of an alternate supplier is anticipated to provide a potential reduction of 25% to 40% in the cost of goods sold and increase gross profit.Botanix Pharmaceuticals' shares jumped nearly 6% in recent trading on Thursday.

ASX:BOT

Track with the FINWIRES app suite

FolioX

Track ASX:BOT in your portfolio

WheelAI

Analyze ASX:BOT options with the wheel strategy

StockInsider

See market sentiment on ASX:BOT